One of the early in vivo efficacy evaluations of oral ONC201 was in an Eμ-myc transgenic mouse model that spontaneously causes metastatic myc-driven aggressive lymphomas by approximately 9 weeks of age [1]. Here, MYC is linked to lymphoma.